363-32-6

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-FLUORO-4-NITROBENZOATE is used as a chemical intermediate for the production of pharmaceuticals. Its unique structure and properties make it a valuable component in the synthesis of various medicinal compounds, contributing to the development of new drugs with specific therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 2-FLUORO-4-NITROBENZOATE serves as an intermediate in the synthesis of agrochemicals. Its role in creating compounds for crop protection and other agricultural applications highlights its versatility and importance in this industry.
Used in Dye Industry:
ETHYL 2-FLUORO-4-NITROBENZOATE is also utilized as an intermediate in the dye industry. Its chemical properties allow it to be a part of the production process for various dyes, which have applications in coloring textiles, plastics, and other materials.
Used in Research and Development:
Due to its unique chemical structure, ETHYL 2-FLUORO-4-NITROBENZOATE is used as a building block in research and development for creating new drugs and materials. Its potential applications in this area are vast, as it can contribute to the advancement of various fields through the creation of innovative products.

InChI:InChI=1/C9H8FNO4/c1-2-15-9(12)7-4-3-6(11(13)14)5-8(7)10/h3-5H,2H2,1H3

Upstream product

• 64-17-5 ethanol 
• 403-23-6 2-fluoro-4-nitrobenzoyl chloride 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 75-03-6 ethyl iodide 
• 7664-93-9 sulfuric acid 
• 1427-07-2 2-fluoro-4-nitrotoluene 

Downstream Products

• 191469-57-5 ethyl 2-fluoro-4-[(3'-methoxymethoxy-4-bromo-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethylnaphtalen-2'-yl)carbamoyl]benzoate 
• 73792-06-0 ethyl-4-amino-2-fluorobenzoate 
• 915391-14-9 C₁₆H₁₃FN₂O₆ 
• 1323276-32-9 C₂₀H₂₁FN₄O₅ 

Relevant academic research and scientific papers

RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION

Modulators of retinoid acid receptor-alpha (RARα) of formula (I) are provided herein, as well as pharmaceutical compositions and methods relating thereto.

POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION AND METHOD FOR DETECTION OF BACTERIAL INFECTION

This invention provides a composition comprising the compound having the structure: ethyl 2-[19F]F-4-nitrobenzoate, and at least one acceptable carrier. This invention also provides a method of detecting the presence of or location of bacteria

RETINOID COMPOUND AND PHARMACEUTICAL COMPOSITION

PROBLEM TO BE SOLVED: To provide a novel retinoid compound that is low in teratogenicity, and a pharmaceutical composition containing said retinoid compound. SOLUTION: Provided are a retinoid compound which is a compound represented by the following formula (1) or a salt thereof, and a pharmaceutical composition containing said retinoid compound. In the formula, R1 represents a halogen atom, and R2 and R3 each independently represent a silyl group. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

Positron Emission Tomography Imaging of Staphylococcus aureus Infection Using a Nitro-Prodrug Analogue of 2-[18F]F- p-Aminobenzoic Acid

Deep-seated bacterial infections caused by pathogens such as Staphylococcus aureus are difficult to diagnose and treat and are thus a major threat to human health. In previous work we demonstrated that positron emission tomography (PET) imaging with 2-[18

N-substituted benzenesulfonyl-substituted benzamide compounds and application thereof to drug preparation

The invention relates toN-substituted benzenesulfonyl-substituted benzamide compounds, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or predrugs of the compounds as well as a preparation method and a pharmaceutical application of th

Synthesis and cardiac imaging of 18F-ligands selective for β1-adrenoreceptors

A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/ β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.

Novel indolyl derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Novel sulfonamides as L-CPT1 inhibitors

The invention is concerned with novel sulfonamide derivatives of formula (I) wherein R2, R3, R4, A, X, Y1, Y2, Y3, Y4 and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.